'Unprecedented' 73% Response Rate With Combo of immunotherapy and a vascular endothelial growth fac

'Unprecedented' 73% Response Rate With Combo in Untreated RCC


https://www.medscape.com/viewarticle/892672?src=WNL_infoc_180902_MSCPEDIT_TEMP2&uac=128445HG&impID=1725962&faf=1

This article and the below associated advice has been received by a small and select group of international investors in IMU from an American advisor who focuses on Australian biotechs.

" One of the peptides developed by IMU's OSU team targets the VEGF receptors. Once of the weakness of cancer cells is their lack of a "good" blood supply to fuel their growth. One of their escape mechanisms is to secrete VEGF to entice nearby capillaries to branch out to the cancer tumor cells. Without a this blood supply it's very hard for a tumor to really grow and metastasize. If an effective anti-VEGF therapy can be delivered you can keep the cancer in check. So I'm not really surprised at this study's results.

Kaumaya's OSU team has a treasure trove of vaccines and peptides that could be used in a wide range of combination therapies for a wide range of cancer types--well beyond breast and gastric cancers. It's only a question of money to do the clinical trials. The science as already there "